Name: Pearce IP
Address: Level 5/20 Bond St, Sydney, NSW, 2000, AU
Telephone: (02) 9023 9988
Price range: $$

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

Celltrion releases the results of Ph III trials of CT-P16 (biosimilar bevacizumab candidate)

By Bioblast Editor | Apr 13, 2022

Read more

Korea Biomedical Review reported that Celltrion released the results of its Ph III trials of CT-P16 (biosimilar bevacizumab candidate) at the American Association for Cancer Research 2022. Celltrion said that CT-P16 demonstrated equivalence in efficacy with Avastin®. Base...
FDA approves Amneal's BLA for Alymsys® (biosimilar bevacizumab)

By Bioblast Editor | Apr 13, 2022

Read more

Amneal Pharmaceuticals announced that the FDA has approved its BLA for Alymsys® (biosimilar bevacizumab) marking the second of three oncology biosimilar approvals Amneal expects to receive in 2022. Alymsys® was developed by mAbxience, and its approval is the third biosimil...
Pearce IP BioBlast w/e 8 April 2022

By Naomi Pearce | Apr 11, 2022

Read more

31 March 22 | Fresenius Kabi announced that it has bought a majority stake (55%) in mAbxience, a company specialising in biosimilars, for an upfront EUR 495 million plus milestone p...
Full Court confirms expert evidence out of fingolimod trial

By Naomi Pearce | Apr 11, 2022

Read more

Novartis AG v Pharmacor Pty Ltd [2022] FCAFC 58

Date:

Court:

Judges:

4 April 2022

Full Federal Court of Australia...
Celltrion announces the launch of Yuflyma® (biosimilar adalimumab) in Canada

By Bioblast Editor | Apr 11, 2022

Read more

Celltrion announced the launch of Yuflyma® (high-concentration, low-volume, citrate-free and latex-free biosimilar adalimumab) in Canada. Yuflyma® is approved in Canada for ten indications: rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthri...
Patent litigation in Australia just got a little cheaper

By Naomi Pearce | Apr 08, 2022

Read more

The Full Court’s refusal of leave to appeal today in Novartis AG v Pharmacor Pty Limited [2022] FCAFC 58 is good news for the cost of patent litigation in Australia: it may have jus...
The recipe for success: CSIRO launches bold new protein roadmap

By Pearce IP | Apr 07, 2022

Read more

In the quest for a more sustainable future, not least of all in response to the pressing issues of climate change and global population growth, innovative agri-technology and foodte...
Alvotech settles with AbbVie in Europe, allowing Stada to commercialise adalimumab biosimilar there

By Bioblast Editor | Apr 06, 2022

Read more

Alvotech announced that it has resolved its patent disputes with AbbVie in Europe and selected markets elsewhere relating to Alvotech’s citrate free, high concentration adalimumab (AVT02, biosimilar to Humira®). This follows the resolution of the US litigation between AbbV...
Australian Government commits to claim damages from originator pharmaceutical companies where generic entry is unduly delayed

By Naomi Pearce | Apr 05, 2022

Read more

In its 2022-23 Budget, the Coalition Government has stated that it will continue to fund litigation against originator pharmaceutical companies that prevent generic versions of thei...
Axantia to commercialise ranibizumab biosimilar in the Middle East

By Bioblast Editor | Apr 04, 2022

Read more

Intas announced that it has signed an exclusive license and supply agreement with Axantia, a Middle Eastern pharmaceutical company, for the commercialisation of ranibizumab (biosimilar Lucentis®) in territories including Saudi Arabia, Jordan, Iraq and Lebanon.